Cullen/Frost Bankers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cullen/Frost Bankers’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31	Closed	-$5.27K	–	1479
2025 Q4	$5.27K	Hold	31	–	–	﹤0.01%	1181
2025 Q3	$4.09K	Sell	31 -61	-66%	-$7.32K	﹤0.01%	1171
2025 Q2	$9.76K	Buy	+92	New	+$9.99K	﹤0.01%	1034
2022 Q4	–	Sell	-10	Closed	-$1K	–	1154
2022 Q3	$1K	Buy	+10	New	+$1.52K	﹤0.01%	1097
2022 Q1	–	Sell	-6	Closed	-$1K	–	1212
2021 Q4	$1K	Hold	6	–	–	﹤0.01%	1128
2021 Q3	$1K	Sell	6 -3	-33%	-$453	﹤0.01%	1182
2021 Q2	$2K	Buy	+9	New	+$1.56K	﹤0.01%	1159
2019 Q2	–	Sell	-654	Closed	-$93K	–	1070
2019 Q1	$93K	Buy	+654	New	+$85.3K	﹤0.01%	483

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cullen/Frost Bankers's JAZZ Position: Q1 2026 in Review

Cullen/Frost Bankers sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 31 shares — an estimated $5.27K sold.

Cullen/Frost Bankers first reported a position in JAZZ in Q1 2019 and held it in 8 quarters. The position peaked at $93K in Q1 2019. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Cullen/Frost Bankers reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Cullen/Frost Bankers sold 31 Jazz Pharmaceuticals shares in Q1 2026, an estimated $5.27K.
Cullen/Frost Bankers first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 8 quarters.
Cullen/Frost Bankers's Jazz Pharmaceuticals position peaked at $93K in Q1 2019.
573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.